In Brief: Haemonetics' John White
This article was originally published in The Gray Sheet
Executive Summary
Haemonetics' John White: Chairman and CEO steps down Jan. 27 at the request of the board of directors, which cites a leveling off in the blood products and processing systems maker's financial performance over the last two years. White is succeeded as CEO by James Peterson, formerly vice chairman and president of Haemonetics International. Succeeding White as chairman is Sir Stuart Burgess, who has been a board member since 1992 and is former CEO of Amersham International. White, who had been CEO since 1985, "helped to grow the company from a $32 mil. business to a global firm with over $300 mil. in revenues," the firm notes. For the three months ended Dec. 27, net revenues decreased 1% to $75.8 mil. Excluding the effect of a $25.2 mil. restructuring charge, net income declined 33% to $4.7 mil...